Aktuellt
SENASTE
The Master Agreement is distinctly positive and adds to the potential sales contribution, which can be very substantial with an exponential increase from the initial first order of SEK 1.7m, if a candidate is approved and the approval includes Biovica’s DiviTum as part of the label (companion diagnostics or CDx). We look forward to Biovica’s Q3 report next week with an update on both sales and the progress made in clinical therapeutic and pharma sales.
LÄS MER
